XM does not provide services to residents of the United States of America.
D
D

DiaSorin


News

Euronext, Pearson, Saint-Gobain

EUROPE RESEARCH ROUNDUP- Euronext, Pearson, Saint-Gobain July 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Euronext, Pearson and Saint-Gobain on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : HSBC cuts target price to EUR 1600 from EUR 1900 * Deutsche Boerse AG DB1Gn.DE : JP Morgan raises target price to EUR 198 from EUR 194 * Euronext NV ENX.PA : JP Morgan cuts target price to EUR 107 from EUR 108 * Pearson PSON.L : JP Morgan cut
A
C
C
D
D
E
E
H
H
L
L
P
P
P
R
S
S
S
A
D
J
S

Italy - Factors to watch on July 30

Italy - Factors to watch on July 30 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Chinese President Xi Jinping and Italian Prime Minister Giorgia Meloni discussed the war in Ukraine and the crisis in the Middle East at a meeting in Beijing on Monday, Meloni's office said.
A
B
E
H
I
L
R
A
D
D
F
I
P
I
U

DiaSorin raises 2024 guidance slightly following Q2 results

UPDATE 1-DiaSorin raises 2024 guidance slightly following Q2 results Adds revenue and adj. core profit in paragraph 3-4, shares movement in 5 July 29 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI raised its guidance slightly for 2024 after reporting on Monday a 9% rise in second-quarter adjusted core profit. The company said it now expects revenue growth this year of between 6%-7% compared to previous guidance of 5%-7% growth, and sees its 2024 adjusted core profit margin at abo
D

DiaSorin slightly raises 2024 guidance following Q2 results

DiaSorin slightly raises 2024 guidance following Q2 results July 29 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Monday slightly hiked guidance for 2024, after its second quarter adjusted core profit rose 9% at a constant exchange rate compared to the same period last yea. The company now expects for 2024 a growth in revenue excluding Covid between 6%-7% compared to previous guidance of 5%-7% growth, and sees its 2024 adjusted core profit margin at about 33% compared to a pr
D

Diasorin Q2 Adj EBITDA At EUR 102 Mln

BRIEF-Diasorin Q2 Adj EBITDA At EUR 102 Mln July 29 (Reuters) - DiaSorin SpA DIAS.MI : FY 2024 GUIDANCE REVISED UPWARDS AT 2023 CONSTANT EXCHANGE RATES, EX-COVID REVENUES: BETWEEN +6% AND +7% (COVID REVENUES EQUAL TO AROUND EUR 30 MILLION) FY 2024 GUIDANCE REVISED UPWARDS, ADJUSTED EBITDA MARGIN: APPROX. 33% Q2 ADJUSTED EBITDA EUR 102 MILLION Q2 RE
D

Italy - Factors to watch on July 29

Italy - Factors to watch on July 29 The following factors could affect Italian markets on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Italian Prime Minister Giorgia Meloni vowed on Sunday to "relaunch" cooperation with China, signing a three-year action plan during her first official visit to Beijing since taking office.
A
E
I
T
D
I
U

Glencore, Rio Tinto, Michelin

EUROPE RESEARCH ROUNDUP-Glencore, Rio Tinto, Michelin July 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Rio Tinto and Michelin, on Monday. HIGHLIGHTS * Arkema SA AKE.PA : JP Morgan raises to neutral from underweight * Glencore GLEN.L : Jefferies raises target price to 600p from 550p * Michelin MICP.PA : HSBC raises to buy from hold * Pirelli & C SpA PIRC.MI : HSBC raises to buy from hold * Rio Tinto RIO.L : Jefferies
A
A
A
A
A
B
B
B
C
C
D
G
G
H
L
A
D
P
R

Diasorin rises on new product clearance from U.S. FDA

BUZZ-Diasorin rises on new product clearance from U.S. FDA ** Shares in Italy's DiaSorin DIAS.MI rise as much as 1.6% after the medical diagnostic group obtained clearance for its new product Liaison Plex Yeast Blood Culture Assay from the U.S. Food and Drug Administration. ** The product is the second multiplexing molecular diagnostic panel on the Liaison PLEX platform and allows the identification of 16 pathogens commonly associated with the presence of fungi in the blood.
D

Diasorin Obtains FDA 510(K) Clearance For Its Liaison Plex Yeast Blood Culture Assay

BRIEF-Diasorin Obtains FDA 510(K) Clearance For Its Liaison Plex Yeast Blood Culture Assay June 5 (Reuters) - DiaSorin SpA DIAS.MI : OBTAINS FDA 510(K) CLEARANCE FOR ITS LIAISON PLEX® YEAST BLOOD CULTURE ASSAY, FOLLOWING LIAISON PLEX SYSTEM CLEARANCE IN MARCH Further company coverage: DIAS.MI (Gdansk Newsroom)
D

Eiffage, Quilter, Ricardo

EUROPE RESEARCH ROUNDUP-Eiffage, Quilter, Ricardo June 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Eiffage, Quilter and Ricardo, on Monday. HIGHLIGHTS * Acciona Energia ANE.MC : Morgan Stanley raises to equalweight from underweight * Eiffage FOUG.PA : Goldman Sachs raises to buy from neutral * Quilter Plc QLT.L : JP Morgan raises to overweight from neutral * Ricardo Plc RCDO.L : Berenberg raises to buy from hold * St.
B
C
C
E
H
H
I
I
J
P
P
R
S
V
D
L
N

ABB Ltd, Capital & Regional Plc, Neste Oyj

EUROPE RESEARCH ROUNDUP- ABB Ltd, Capital & Regional Plc, Neste Oyj May 15 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ABB Ltd, Capital & Regional Plc and Neste Oyj, on Wednesday. HIGHLIGHTS * ABB Ltd ABBN.S : TD Cowen raises target price to CHF 46 from CHF 38 * Capital & Regional Plc CAL.L : Berenberg cuts target price to 65p from 68p * Hannover Re HNRGN.DE : HSBC raises target price to EUR 235 from EUR 225 * Neste Oyj NESTE.H
A
A
A
B
B
C
C
D
E
E
G
H
N
A
D



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.